HydRegen appoint Matthew Hodges to evolve its lead catalyst technology product
HydRegen, the revolutionary bioscience company, is excited to announce the appointment of Matthew Hodges as Commercial and Operations Lead, directing the commercial strategy and assisting in the development of its lead product. Matt brings a strong background in building businesses for fundraising, winning public grant applications and creating successful partnerships in both commercial and scientific areas.
Matt:
I am very passionate about developing and implementing innovative biotech-based solutions to globally demanding issues, such as decarbonisation, and am pleased to be supporting HydRegen on their mission to provide cleaner, safer and more efficient chemical manufacture
Matthew is an experienced commercial business development leader having worked with Oxford Biotrans from its founding as an Oxford University biotech spin-out through to first product launch, managing production, supply chain and sales functions, and driving its R&D activity. Previously, he has worked with leading consultancies on a range of assignments for major corporates in consumer and pharma markets and has provided advisory board commercial and strategic advice at a number of biotech start-ups. He has a strong track record of identifying successful routes to market, driving key studies required to enter new markets and developing customer pipelines.
HydRegen is developing sustainable bio-based manufacturing technologies, primarily for the fine chemicals and pharmaceutical sectors, to decarbonise existing biocatalysis processes and replace typical precious-metal catalysts for hydrogenation reactions.
As part of its development, HydRegen works in collaboration with industry leading companies to implement greener and less wasteful manufacturing processes to reduce their costs and environmental impact.
Since spinning out from the University of Oxford in 2021, HydRegen has focused on implementation of its new strategies to reduce the environmental impact of active pharmaceutical ingredient (API) manufacturing. With a vision to replace finite resources like metals, with environmentally and economically sustainable alternatives like hydrogen gas, HydRegen is addressing the unmet needs in the chemical sector.
Dr Holly Reeve, CEO at HydRegen said: “We are really excited for Matt to be part of the team at HydRegen. His extensive experience in commercial development is hugely valuable as we look to take our lead catalyst technology product closer to commercialisation. Under his guidance we have a fantastic opportunity to build on our solution to help our clients successfully reach their net zero goals across a wide range of applications.”
Matt Hodges, Commercial Operations Lead at HydRegen comments: “I have known HydRegen for some time and am proud to be part of such a diverse and innovative team, utilising my skillset to accelerate them on their journey to a sustainable chemical sector. I am very passionate about developing and implementing innovative biotech-based solutions to globally demanding issues, such as decarbonisation, and am pleased to be supporting HydRegen on their mission to provide cleaner, safer and more efficient chemical manufacture.”